Loading...
Market
What will be the public health impact of the First To Know Syphilis Test by end of 2024?
1
Resolution / Starting Odds
Significant decrease in syphilis cases • 25%
Moderate decrease in syphilis cases • 25%
No significant change in syphilis cases • 25%
Increase in syphilis cases • 25%
Public health reports and studies
Story
FDA Approves NOWDiagnostics' First At-Home Syphilis Test
Aug 16, 2024, 04:04 PM
The U.S. Food and Drug Administration (FDA) has granted De Novo Marketing Authorization to NOWDiagnostics for the First To Know Syphilis Test, marking the first at-home, over-the-counter test to detect Treponema pallidum (syphilis) antibodies in human blood. The test, developed by NOWDiagnostics, delivers results in about 15 minutes and aims to increase screening rates for syphilis, a sexually transmitted disease. Despite its convenience, the FDA cautioned that the test alone is not sufficient for a complete diagnosis, and further medical consultation is recommended.
View original story
Similar markets
Online Retailers • 25%
Pharmacy Chains • 25%
Healthcare Providers • 25%
Other • 25%
Less than 3 stars • 25%
3 to 3.9 stars • 25%
4 to 4.4 stars • 25%
4.5 stars or more • 25%
Less than 10,000 • 25%
10,000 to 20,000 • 25%
20,001 to 30,000 • 25%
More than 30,000 • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Very Positive • 25%
Somewhat Positive • 25%
Neutral • 25%
Negative • 25%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Increase by more than 20% • 33%
Increase by less than 20% • 33%
No significant change • 33%
Yes • 50%
No • 50%
Increased access to reproductive health services • 33%
No change in access to reproductive health services • 33%
Decreased access to reproductive health services • 33%